- Home
- DRCT vs ELEV Comparison
DRCT vs ELEV Comparison
Compare DRCT & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRCT
- ELEV
- Stock Information
- Founded
- DRCT 2018
- ELEV 2019
- Country
- DRCT United States
- ELEV United States
- Employees
- DRCT 79
- ELEV N/A
- Industry
- DRCT Computer Software: Programming Data Processing
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- DRCT Technology
- ELEV Health Care
- Exchange
- DRCT Nasdaq
- ELEV Nasdaq
- Market Cap
- DRCT 16.7M
- ELEV 22.0M
- IPO Year
- DRCT 2022
- ELEV 2021
- Fundamental
- Price
- DRCT $0.69
- ELEV $0.36
- Analyst Decision
- DRCT Strong Buy
- ELEV Buy
- Analyst Count
- DRCT 1
- ELEV 6
- Target Price
- DRCT $6.00
- ELEV $2.94
- AVG Volume (30 Days)
- DRCT 2.9M
- ELEV 996.3K
- Earning Date
- DRCT 05-06-2025
- ELEV 05-16-2025
- Dividend Yield
- DRCT N/A
- ELEV N/A
- EPS Growth
- DRCT N/A
- ELEV N/A
- EPS
- DRCT N/A
- ELEV N/A
- Revenue
- DRCT $48,170,000.00
- ELEV N/A
- Revenue This Year
- DRCT $53.01
- ELEV N/A
- Revenue Next Year
- DRCT $11.11
- ELEV N/A
- P/E Ratio
- DRCT N/A
- ELEV N/A
- Revenue Growth
- DRCT N/A
- ELEV N/A
- 52 Week Low
- DRCT $0.44
- ELEV $0.22
- 52 Week High
- DRCT $6.59
- ELEV $4.33
- Technical
- Relative Strength Index (RSI)
- DRCT 48.55
- ELEV 52.69
- Support Level
- DRCT $0.81
- ELEV $0.34
- Resistance Level
- DRCT $1.23
- ELEV $0.36
- Average True Range (ATR)
- DRCT 0.14
- ELEV 0.03
- MACD
- DRCT 0.02
- ELEV 0.00
- Stochastic Oscillator
- DRCT 26.24
- ELEV 50.00
About DRCT Direct Digital Holdings Inc.
Direct Digital Holdings Inc is an end-to-end, full-service programmatic advertising platform primarily focused on providing advertising technology, data-driven campaign optimization, and other solutions to underserved and less efficient markets on both the buy-side and sell-side of the digital advertising ecosystem. The company operates two reportable segments: sell-side advertising, which includes the results of Colossus Media, and buy-side advertising, which includes the results of Orange 142 and Huddled Masses. All of the company's revenues are attributed to the United States.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.